Evidence map›Paper›PMID 27916783›Full record

Trial reportEndocrine journal2017

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.

Ryotaro Bouchi, Yujiro Nakano, Tatsuya Fukuda, Takato Takeuchi, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Endocrine journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03590626 (Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease), which is not on this map. Cited by 63 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 13 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03590626 nacompletedstarted 2019, after this paper: background citation

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Ran2019Enrolled60Registered outcomes7Posted comparisons0ConditionsNon Alcoholic Fatty Liver Disease, Type2 Diabetes MellitusArmsDulaglutide
PMID 27732328PMID 24842985PMID 24742660PMID 26089386PMID 25018121PMID 22554256PMID 25482832PMID 23383649PMID 22431131PMID 22025886other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 13 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. GLP-1a: Going beyond Traditional Use.International journal of molecular sciences · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ryotaro BouchiDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Yujiro Nakano
Tatsuya Fukuda
Takato Takeuchi
Masanori Murakami
Isao Minami
Hajime Izumiyama
Koshi Hashimoto
Takanobu Yoshimoto
Yoshihiro Ogawa
Tokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liraglutide, an analogue of human glucagon-like peptide 1, reduces cardiovascular events in patients with type 2 diabetes; however, it has still been unknown by which mechanisms liraglutide could reduce cardiovascular events. Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study. Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation. Primary endpoint was the change in viscera fat are (VFA, cm

Indexed as

AdiposityAlbuminuriaCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic CardiomyopathiesDiabetic NephropathiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIntra-Abdominal FatJapanLiraglutideHypoglycemic AgentsInsulinLiraglutide

Identifiers

PMID27916783
OpenAlexW2558199233

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.